293 related articles for article (PubMed ID: 16273807)
1. Rheumatoid arthritis registries in Sweden.
van Vollenhoven RF; Askling J
Clin Exp Rheumatol; 2005; 23(5 Suppl 39):S195-200. PubMed ID: 16273807
[TBL] [Abstract][Full Text] [Related]
2. Rheumatoid arthritis databases in Finland.
Sokka T
Clin Exp Rheumatol; 2005; 23(5 Suppl 39):S201-4. PubMed ID: 16273808
[TBL] [Abstract][Full Text] [Related]
3. DANBIO: a nationwide registry of biological therapies in Denmark.
Hetland ML
Clin Exp Rheumatol; 2005; 23(5 Suppl 39):S205-7. PubMed ID: 16273809
[TBL] [Abstract][Full Text] [Related]
4. An Early Rheumatoid Arthritis Treatment Evaluation Registry (ERATER) in the United States.
Sokka T; Pincus T
Clin Exp Rheumatol; 2005; 23(5 Suppl 39):S178-81. PubMed ID: 16273804
[TBL] [Abstract][Full Text] [Related]
5. Can rheumatoid arthritis (RA) registries provide contextual safety data for modern RA clinical trials? The case for mortality and cardiovascular disease.
Michaud K; Berglind N; Franzén S; Frisell T; Garwood C; Greenberg JD; Ho M; Holmqvist M; Horne L; Inoue E; Nyberg F; Pappas DA; Reed G; Symmons D; Tanaka E; Tran TN; Verstappen SM; Wesby-van Swaay E; Yamanaka H; Askling J
Ann Rheum Dis; 2016 Oct; 75(10):1797-805. PubMed ID: 26857699
[TBL] [Abstract][Full Text] [Related]
6. Rheumatoid arthritis initial therapy: unanswered questions.
O'Dell J
J Rheumatol Suppl; 2005 Jan; 72():14-6. PubMed ID: 15660457
[TBL] [Abstract][Full Text] [Related]
7. A Norwegian DMARD register: prescriptions of DMARDs and biological agents to patients with inflammatory rheumatic diseases.
Kvien TK; Heiberg ; Lie E; Kaufmann C; Mikkelsen K; Nordvåg BY; Rødevand E
Clin Exp Rheumatol; 2005; 23(5 Suppl 39):S188-94. PubMed ID: 16273806
[TBL] [Abstract][Full Text] [Related]
8. The role of registries in the treatment of rheumatoid arthritis with biologic disease-modifying anti-rheumatic drugs.
Pombo-Suarez M; Gomez-Reino J
Pharmacol Res; 2019 Oct; 148():104410. PubMed ID: 31461667
[TBL] [Abstract][Full Text] [Related]
9. The British Society for Rheumatology Biologics Register: 6 years on.
Hyrich KL; Watson KD; Isenberg DA; Symmons DP;
Rheumatology (Oxford); 2008 Oct; 47(10):1441-3. PubMed ID: 18596052
[No Abstract] [Full Text] [Related]
10. Joint damage progression in patients with rheumatoid arthritis in clinical remission: do biologics perform better than synthetic antirheumatic drugs?
Ciubotariu E; Gabay C; Finckh A;
J Rheumatol; 2014 Aug; 41(8):1576-82. PubMed ID: 25028383
[TBL] [Abstract][Full Text] [Related]
11. British Society for Rheumatology Biologics Register.
Silman A; Symmons D; Scott DG; Griffiths I
Ann Rheum Dis; 2003 Nov; 62 Suppl 2(Suppl 2):ii28-9. PubMed ID: 14532144
[TBL] [Abstract][Full Text] [Related]
12. Does cancer that occurs during or after anti-tumor necrosis factor therapy have a worse prognosis? A national assessment of overall and site-specific cancer survival in rheumatoid arthritis patients treated with biologic agents.
Raaschou P; Simard JF; Neovius M; Askling J;
Arthritis Rheum; 2011 Jul; 63(7):1812-22. PubMed ID: 21305513
[TBL] [Abstract][Full Text] [Related]
13. Real-world utilization of DMARDs and biologics in rheumatoid arthritis: the RADIUS (Rheumatoid Arthritis Disease-Modifying Anti-Rheumatic Drug Intervention and Utilization Study) study.
Gibofsky A; Palmer WR; Goldman JA; Lautzenheiser RL; Markenson JA; Weaver A; Schiff MH; Keystone EC; Paulus HE; Harrison MJ; Whitmore JB; Leff JA
Curr Med Res Opin; 2006 Jan; 22(1):169-83. PubMed ID: 16393443
[TBL] [Abstract][Full Text] [Related]
14. Real-world effectiveness of select biologic and DMARD monotherapy and combination therapy in the treatment of rheumatoid arthritis: results from the RADIUS observational registry.
Weaver AL; Lautzenheiser RL; Schiff MH; Gibofsky A; Perruquet JL; Luetkemeyer J; Paulus HE; Xia HA; Leff JA;
Curr Med Res Opin; 2006 Jan; 22(1):185-98. PubMed ID: 16393444
[TBL] [Abstract][Full Text] [Related]
15. Effect of treatment with biological agents for arthritis in Australia: the Australian Rheumatology Association Database.
Buchbinder R; March L; Lassere M; Briggs AM; Portek I; Reid C; Meehan A; Henderson L; Wengier L; van den Haak R
Intern Med J; 2007 Sep; 37(9):591-600. PubMed ID: 17573817
[TBL] [Abstract][Full Text] [Related]
16. Individual variations in treatment decisions by Swedish rheumatologists regarding biological drugs for rheumatoid arthritis.
Kalkan A; Hallert E; Carlsson P; Roback K; Sjöwall C
Scand J Rheumatol; 2015; 44(4):265-70. PubMed ID: 26202443
[TBL] [Abstract][Full Text] [Related]
17. A comparison of patient characteristics and outcomes in selected European and U.S. rheumatoid arthritis registries.
Curtis JR; Jain A; Askling J; Bridges SL; Carmona L; Dixon W; Finckh A; Hyrich K; Greenberg JD; Kremer J; Listing J; Michaud K; Mikuls T; Shadick N; Solomon DH; Weinblatt ME; Wolfe F; Zink A
Semin Arthritis Rheum; 2010 Aug; 40(1):2-14.e1. PubMed ID: 20674669
[TBL] [Abstract][Full Text] [Related]
18. Health-related quality of life and continuation rate on first-line anti-tumour necrosis factor therapy among rheumatoid arthritis patients from the Australian Rheumatology Association Database.
Staples MP; March L; Lassere M; Reid C; Buchbinder R
Rheumatology (Oxford); 2011 Jan; 50(1):166-75. PubMed ID: 20929971
[TBL] [Abstract][Full Text] [Related]
19. The Corrona US registry of rheumatic and autoimmune diseases.
Kremer JM
Clin Exp Rheumatol; 2016; 34(5 Suppl 101):S96-S99. PubMed ID: 27762197
[TBL] [Abstract][Full Text] [Related]
20. Expanding role of biologic agents in rheumatoid arthritis.
Kalden JR
J Rheumatol Suppl; 2002 Nov; 66():27-37. PubMed ID: 12435166
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
